Logo image of DWTX

DOGWOOD THERAPEUTICS INC (DWTX) Stock Price, Quote, News and Summary

NASDAQ:DWTX - Nasdaq - US92829J2033 - Common Stock

3.15  +1.28 (+68.45%)

After market: 2.9712 -0.18 (-5.68%)

DWTX Quote and Key Statistics

DOGWOOD THERAPEUTICS INC

NASDAQ:DWTX (1/21/2025, 8:00:02 PM)

After market: 2.9712 -0.18 (-5.68%)

3.15

+1.28 (+68.45%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap4.19M
Shares1.33M
Float1.05M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO12-17 2020-12-17

DWTX Financial Highlights

Industry RankSector Rank
PM (TTM) N/A
ROA -145.66%
ROE -168.89%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-36.67%
Sales Q2Q%N/A
EPS 1Y (TTM)20.61%
Revenue 1Y (TTM)N/A
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

DWTX Performance and Technical Analysis

Chartmill TA Rating
Chartmill Setup Rating

DWTX short term performance overview.The bars show the price performance of DWTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20

DWTX long term performance overview.The bars show the price performance of DWTX in the last 1, 2 and 3 years. 1 year 2 years 3 years
DWTX Daily chart

DWTX Ownership and Analysts

Ownership
Inst Owners3.6%
Ins Owners6.74%
Short Float %1.27%
Short Ratio0.28
Analysts
Analysts80
Price TargetN/A
EPS Next Y6.31%
Revenue Next YearN/A

DWTX Latest News and Analysis

News Image
9 hours ago - Chartmill

Get insights into the top gainers and losers of Tuesday's after-hours session.

Get insights into the top gainers and losers of Tuesday's after-hours session.

News Image
17 hours ago - Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025

ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company...

News Image
2 months ago - Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

- IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue...

News Image
3 months ago - Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

- Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) formed in October by combination of Virios Therapeutics, Inc. and Pharmagesic (Holdings) Inc., 100% parent...

About DWTX

Company Profile

DWTX logo image Dogwood Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Alpharetta, Georgia and currently employs 4 full-time employees. The company went IPO on 2020-12-17. Dogwood Therapeutics, Inc., formerly Virios Therapeutics, Inc., is focused on the clinical development of three assets, Halneuron, IMC-1, and IMC-2. Halneuron is in Phase 2b development as a non-opioid, Nav 1.7 inhibitor, to treat the neuropathic pain associated with chemotherapy treatment. Halneuron is an injectable formulation of Tetrodotoxin, a novel small molecule with action exclusively on the peripheral nervous system. IMC-2 (valacyclovir + celecoxib) is in Phase 2 development as a combination antiviral treatment for Long-COVID (LC). IMC-1 (famciclovir (FM) + celecoxib) is Phase 3 development ready as a combination antiviral treatment for FM. IMC-1 has been granted fast track designation by the FDA. IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms.

Company Info

DOGWOOD THERAPEUTICS INC

44 Milton Avenue

Alpharetta GEORGIA US

Employees: 4

Company Website: https://dwtx.com/

Investor Relations: http://ir.virios.com

Phone: 18666208655

DWTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 16.06 305.03B
AMGN AMGEN INC 14.3 147.72B
GILD GILEAD SCIENCES INC 20.98 115.85B
VRTX VERTEX PHARMACEUTICALS INC 839 110.19B
REGN REGENERON PHARMACEUTICALS 15.14 75.58B
ARGX ARGENX SE - ADR N/A 38.71B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 34.18B
BNTX BIONTECH SE-ADR N/A 28.26B
ONC BEIGENE LTD-ADR N/A 23.28B
NTRA NATERA INC N/A 22.11B
BIIB BIOGEN INC 8.63 20.54B
UTHR UNITED THERAPEUTICS CORP 16.16 16.43B